nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—CYP2D6—Temsirolimus—kidney cancer	0.0547	0.372	CbGbCtD
L-DOPA—CYP2D6—Pazopanib—kidney cancer	0.0287	0.195	CbGbCtD
L-DOPA—CYP2D6—Erlotinib—kidney cancer	0.0205	0.139	CbGbCtD
L-DOPA—CYP2D6—Sorafenib—kidney cancer	0.0167	0.113	CbGbCtD
L-DOPA—CYP2D6—Vinblastine—kidney cancer	0.0165	0.112	CbGbCtD
L-DOPA—L-Histidine—HARS—kidney cancer	0.0109	0.589	CrCbGaD
L-DOPA—CYP2D6—Doxorubicin—kidney cancer	0.0101	0.0687	CbGbCtD
L-DOPA—PSIP1—nephron tubule—kidney cancer	0.00998	0.0745	CbGeAlD
L-DOPA—PSIP1—renal system—kidney cancer	0.00907	0.0677	CbGeAlD
L-DOPA—PSIP1—cortex of kidney—kidney cancer	0.00854	0.0638	CbGeAlD
L-DOPA—PSIP1—gonad—kidney cancer	0.00814	0.0607	CbGeAlD
L-DOPA—SLC7A8—nephron tubule—kidney cancer	0.00658	0.0491	CbGeAlD
L-DOPA—SLC7A8—renal system—kidney cancer	0.00598	0.0446	CbGeAlD
L-DOPA—SLC7A8—kidney—kidney cancer	0.00578	0.0432	CbGeAlD
L-DOPA—DDC—nephron tubule—kidney cancer	0.00569	0.0425	CbGeAlD
L-DOPA—SLC7A8—cortex of kidney—kidney cancer	0.00563	0.042	CbGeAlD
L-DOPA—CYP2D6—urine—kidney cancer	0.00552	0.0412	CbGeAlD
L-DOPA—SLC7A8—gonad—kidney cancer	0.00536	0.04	CbGeAlD
L-DOPA—DDC—renal system—kidney cancer	0.00517	0.0386	CbGeAlD
L-DOPA—SLC7A5—nephron tubule—kidney cancer	0.0051	0.0381	CbGeAlD
L-DOPA—DDC—kidney—kidney cancer	0.005	0.0373	CbGeAlD
L-DOPA—DDC—cortex of kidney—kidney cancer	0.00487	0.0364	CbGeAlD
L-DOPA—SLC7A5—cortex of kidney—kidney cancer	0.00436	0.0326	CbGeAlD
L-DOPA—SLC15A1—nephron tubule—kidney cancer	0.00423	0.0316	CbGeAlD
L-DOPA—SLC7A5—gonad—kidney cancer	0.00416	0.031	CbGeAlD
L-DOPA—SLC7A5—cardiac atrium—kidney cancer	0.00415	0.031	CbGeAlD
L-DOPA—SLC7A5—Sirolimus—Temsirolimus—kidney cancer	0.00407	0.344	CbGdCrCtD
L-DOPA—SLC7A5—Sirolimus—Everolimus—kidney cancer	0.00407	0.344	CbGdCrCtD
L-DOPA—SLC16A10—nephron tubule—kidney cancer	0.0039	0.0291	CbGeAlD
L-DOPA—SLC15A1—renal system—kidney cancer	0.00385	0.0287	CbGeAlD
L-DOPA—SLC15A1—kidney—kidney cancer	0.00372	0.0278	CbGeAlD
L-DOPA—PSIP1—Vinblastine—Vincristine—kidney cancer	0.00369	0.312	CbGdCrCtD
L-DOPA—SLC16A10—cortex of kidney—kidney cancer	0.00334	0.0249	CbGeAlD
L-DOPA—SLC16A10—gonad—kidney cancer	0.00318	0.0238	CbGeAlD
L-DOPA—Masoprocol—IGF1R—kidney cancer	0.00317	0.171	CrCbGaD
L-DOPA—Isoprenaline—MAPK1—kidney cancer	0.00172	0.0927	CrCbGaD
L-DOPA—CYP2D6—renal system—kidney cancer	0.00135	0.0101	CbGeAlD
L-DOPA—CYP2D6—kidney—kidney cancer	0.0013	0.00974	CbGeAlD
L-DOPA—Aminosalicylic Acid—PTGS1—kidney cancer	0.00075	0.0405	CrCbGaD
L-DOPA—Mesalazine—PTGS1—kidney cancer	0.000588	0.0318	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—kidney cancer	0.000429	0.0232	CrCbGaD
L-DOPA—Isoprenaline—CYP1A1—kidney cancer	0.000369	0.0199	CrCbGaD
L-DOPA—Rash—Everolimus—kidney cancer	0.000364	0.000706	CcSEcCtD
L-DOPA—Dermatitis—Everolimus—kidney cancer	0.000363	0.000705	CcSEcCtD
L-DOPA—Headache—Vinblastine—kidney cancer	0.000363	0.000704	CcSEcCtD
L-DOPA—Angioedema—Paclitaxel—kidney cancer	0.000362	0.000703	CcSEcCtD
L-DOPA—Purpura—Doxorubicin—kidney cancer	0.000361	0.000702	CcSEcCtD
L-DOPA—Headache—Everolimus—kidney cancer	0.000361	0.000701	CcSEcCtD
L-DOPA—Hypotension—Gemcitabine—kidney cancer	0.000361	0.000701	CcSEcCtD
L-DOPA—Abdominal pain—Dactinomycin—kidney cancer	0.000361	0.0007	CcSEcCtD
L-DOPA—Asthenia—Sorafenib—kidney cancer	0.000359	0.000697	CcSEcCtD
L-DOPA—Malaise—Paclitaxel—kidney cancer	0.000358	0.000694	CcSEcCtD
L-DOPA—Syncope—Paclitaxel—kidney cancer	0.000356	0.00069	CcSEcCtD
L-DOPA—Leukopenia—Paclitaxel—kidney cancer	0.000355	0.000689	CcSEcCtD
L-DOPA—Hypersensitivity—Sunitinib—kidney cancer	0.000355	0.000689	CcSEcCtD
L-DOPA—Decreased appetite—Vincristine—kidney cancer	0.000354	0.000688	CcSEcCtD
L-DOPA—Pruritus—Sorafenib—kidney cancer	0.000354	0.000688	CcSEcCtD
L-DOPA—Vomiting—Erlotinib—kidney cancer	0.000354	0.000687	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Vincristine—kidney cancer	0.000352	0.000683	CcSEcCtD
L-DOPA—Fatigue—Vincristine—kidney cancer	0.000351	0.000682	CcSEcCtD
L-DOPA—Rash—Erlotinib—kidney cancer	0.000351	0.000681	CcSEcCtD
L-DOPA—Dermatitis—Erlotinib—kidney cancer	0.000351	0.00068	CcSEcCtD
L-DOPA—Palpitations—Paclitaxel—kidney cancer	0.000351	0.00068	CcSEcCtD
L-DOPA—Insomnia—Gemcitabine—kidney cancer	0.00035	0.000679	CcSEcCtD
L-DOPA—Headache—Erlotinib—kidney cancer	0.000349	0.000677	CcSEcCtD
L-DOPA—Loss of consciousness—Paclitaxel—kidney cancer	0.000349	0.000677	CcSEcCtD
L-DOPA—Pain—Vincristine—kidney cancer	0.000349	0.000676	CcSEcCtD
L-DOPA—Constipation—Vincristine—kidney cancer	0.000349	0.000676	CcSEcCtD
L-DOPA—Pain in extremity—Doxorubicin—kidney cancer	0.000348	0.000676	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	0.000348	0.000676	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—kidney cancer	0.000348	0.000676	CcSEcCtD
L-DOPA—Paraesthesia—Gemcitabine—kidney cancer	0.000347	0.000674	CcSEcCtD
L-DOPA—Flushing—Capecitabine—kidney cancer	0.000347	0.000673	CcSEcCtD
L-DOPA—Cough—Paclitaxel—kidney cancer	0.000346	0.000672	CcSEcCtD
L-DOPA—Asthenia—Sunitinib—kidney cancer	0.000346	0.000671	CcSEcCtD
L-DOPA—Dyspnoea—Gemcitabine—kidney cancer	0.000345	0.000669	CcSEcCtD
L-DOPA—Nausea—Vinblastine—kidney cancer	0.000344	0.000668	CcSEcCtD
L-DOPA—Somnolence—Gemcitabine—kidney cancer	0.000344	0.000667	CcSEcCtD
L-DOPA—Convulsion—Paclitaxel—kidney cancer	0.000344	0.000667	CcSEcCtD
L-DOPA—Nausea—Everolimus—kidney cancer	0.000343	0.000665	CcSEcCtD
L-DOPA—Diarrhoea—Sorafenib—kidney cancer	0.000343	0.000665	CcSEcCtD
L-DOPA—Hypertension—Paclitaxel—kidney cancer	0.000342	0.000665	CcSEcCtD
L-DOPA—Pruritus—Sunitinib—kidney cancer	0.000341	0.000662	CcSEcCtD
L-DOPA—Chest pain—Paclitaxel—kidney cancer	0.000338	0.000655	CcSEcCtD
L-DOPA—Anxiety—Paclitaxel—kidney cancer	0.000337	0.000653	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—kidney cancer	0.000336	0.0182	CrCbGaD
L-DOPA—Decreased appetite—Gemcitabine—kidney cancer	0.000336	0.000652	CcSEcCtD
L-DOPA—Hypersensitivity—Dactinomycin—kidney cancer	0.000336	0.000652	CcSEcCtD
L-DOPA—Arrhythmia—Capecitabine—kidney cancer	0.000334	0.000648	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000334	0.000648	CcSEcCtD
L-DOPA—Discomfort—Paclitaxel—kidney cancer	0.000334	0.000647	CcSEcCtD
L-DOPA—Fatigue—Gemcitabine—kidney cancer	0.000333	0.000647	CcSEcCtD
L-DOPA—Gastrointestinal pain—Vincristine—kidney cancer	0.000333	0.000647	CcSEcCtD
L-DOPA—Dizziness—Sorafenib—kidney cancer	0.000331	0.000643	CcSEcCtD
L-DOPA—Pain—Gemcitabine—kidney cancer	0.000331	0.000642	CcSEcCtD
L-DOPA—Constipation—Gemcitabine—kidney cancer	0.000331	0.000642	CcSEcCtD
L-DOPA—Nausea—Erlotinib—kidney cancer	0.000331	0.000642	CcSEcCtD
L-DOPA—Alopecia—Capecitabine—kidney cancer	0.00033	0.000641	CcSEcCtD
L-DOPA—Dry mouth—Paclitaxel—kidney cancer	0.00033	0.000641	CcSEcCtD
L-DOPA—Diarrhoea—Sunitinib—kidney cancer	0.00033	0.00064	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—kidney cancer	0.000328	0.000636	CcSEcCtD
L-DOPA—Mental disorder—Capecitabine—kidney cancer	0.000328	0.000636	CcSEcCtD
L-DOPA—Asthenia—Dactinomycin—kidney cancer	0.000327	0.000635	CcSEcCtD
L-DOPA—Confusional state—Paclitaxel—kidney cancer	0.000326	0.000633	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—kidney cancer	0.000326	0.000633	CcSEcCtD
L-DOPA—Oedema—Paclitaxel—kidney cancer	0.000324	0.000628	CcSEcCtD
L-DOPA—Abdominal pain—Vincristine—kidney cancer	0.000322	0.000625	CcSEcCtD
L-DOPA—Flatulence—Capecitabine—kidney cancer	0.000321	0.000622	CcSEcCtD
L-DOPA—Dysgeusia—Capecitabine—kidney cancer	0.000319	0.000619	CcSEcCtD
L-DOPA—Dizziness—Sunitinib—kidney cancer	0.000319	0.000618	CcSEcCtD
L-DOPA—Feeling abnormal—Gemcitabine—kidney cancer	0.000319	0.000618	CcSEcCtD
L-DOPA—Shock—Paclitaxel—kidney cancer	0.000318	0.000618	CcSEcCtD
L-DOPA—Vomiting—Sorafenib—kidney cancer	0.000318	0.000618	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000318	0.000618	CcSEcCtD
L-DOPA—Thrombocytopenia—Paclitaxel—kidney cancer	0.000317	0.000615	CcSEcCtD
L-DOPA—Rash—Sorafenib—kidney cancer	0.000316	0.000613	CcSEcCtD
L-DOPA—Dermatitis—Sorafenib—kidney cancer	0.000315	0.000612	CcSEcCtD
L-DOPA—Back pain—Capecitabine—kidney cancer	0.000315	0.000611	CcSEcCtD
L-DOPA—Headache—Sorafenib—kidney cancer	0.000314	0.000609	CcSEcCtD
L-DOPA—Muscle spasms—Capecitabine—kidney cancer	0.000313	0.000607	CcSEcCtD
L-DOPA—Hyperhidrosis—Paclitaxel—kidney cancer	0.000313	0.000607	CcSEcCtD
L-DOPA—Diarrhoea—Dactinomycin—kidney cancer	0.000312	0.000606	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—kidney cancer	0.000312	0.000605	CcSEcCtD
L-DOPA—Anorexia—Paclitaxel—kidney cancer	0.000309	0.000599	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—kidney cancer	0.000308	0.000598	CcSEcCtD
L-DOPA—Vision blurred—Capecitabine—kidney cancer	0.000307	0.000595	CcSEcCtD
L-DOPA—Vomiting—Sunitinib—kidney cancer	0.000306	0.000595	CcSEcCtD
L-DOPA—Tremor—Capecitabine—kidney cancer	0.000305	0.000592	CcSEcCtD
L-DOPA—Rash—Sunitinib—kidney cancer	0.000304	0.00059	CcSEcCtD
L-DOPA—Dermatitis—Sunitinib—kidney cancer	0.000304	0.000589	CcSEcCtD
L-DOPA—Hypotension—Paclitaxel—kidney cancer	0.000302	0.000587	CcSEcCtD
L-DOPA—Ill-defined disorder—Capecitabine—kidney cancer	0.000302	0.000586	CcSEcCtD
L-DOPA—Headache—Sunitinib—kidney cancer	0.000302	0.000586	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—kidney cancer	0.000301	0.000584	CcSEcCtD
L-DOPA—Anaemia—Capecitabine—kidney cancer	0.000301	0.000584	CcSEcCtD
L-DOPA—Hypersensitivity—Vincristine—kidney cancer	0.0003	0.000583	CcSEcCtD
L-DOPA—Nausea—Sorafenib—kidney cancer	0.000297	0.000577	CcSEcCtD
L-DOPA—Malaise—Capecitabine—kidney cancer	0.000294	0.00057	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—kidney cancer	0.000293	0.000569	CcSEcCtD
L-DOPA—Insomnia—Paclitaxel—kidney cancer	0.000293	0.000568	CcSEcCtD
L-DOPA—Asthenia—Vincristine—kidney cancer	0.000292	0.000568	CcSEcCtD
L-DOPA—Syncope—Capecitabine—kidney cancer	0.000292	0.000566	CcSEcCtD
L-DOPA—Leukopenia—Capecitabine—kidney cancer	0.000291	0.000565	CcSEcCtD
L-DOPA—Paraesthesia—Paclitaxel—kidney cancer	0.000291	0.000564	CcSEcCtD
L-DOPA—Vomiting—Dactinomycin—kidney cancer	0.00029	0.000563	CcSEcCtD
L-DOPA—Dyspnoea—Paclitaxel—kidney cancer	0.000289	0.00056	CcSEcCtD
L-DOPA—Somnolence—Paclitaxel—kidney cancer	0.000288	0.000559	CcSEcCtD
L-DOPA—Palpitations—Capecitabine—kidney cancer	0.000288	0.000558	CcSEcCtD
L-DOPA—Rash—Dactinomycin—kidney cancer	0.000288	0.000558	CcSEcCtD
L-DOPA—Nausea—Sunitinib—kidney cancer	0.000286	0.000555	CcSEcCtD
L-DOPA—Loss of consciousness—Capecitabine—kidney cancer	0.000286	0.000555	CcSEcCtD
L-DOPA—Dyspepsia—Paclitaxel—kidney cancer	0.000285	0.000553	CcSEcCtD
L-DOPA—Cough—Capecitabine—kidney cancer	0.000284	0.000551	CcSEcCtD
L-DOPA—Decreased appetite—Paclitaxel—kidney cancer	0.000281	0.000546	CcSEcCtD
L-DOPA—Hypertension—Capecitabine—kidney cancer	0.000281	0.000545	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.00028	0.000543	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000279	0.000542	CcSEcCtD
L-DOPA—Fatigue—Paclitaxel—kidney cancer	0.000279	0.000542	CcSEcCtD
L-DOPA—Diarrhoea—Vincristine—kidney cancer	0.000279	0.000541	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—kidney cancer	0.000278	0.00054	CcSEcCtD
L-DOPA—Asthenia—Gemcitabine—kidney cancer	0.000277	0.000538	CcSEcCtD
L-DOPA—Chest pain—Capecitabine—kidney cancer	0.000277	0.000538	CcSEcCtD
L-DOPA—Pain—Paclitaxel—kidney cancer	0.000277	0.000537	CcSEcCtD
L-DOPA—Constipation—Paclitaxel—kidney cancer	0.000277	0.000537	CcSEcCtD
L-DOPA—Anxiety—Capecitabine—kidney cancer	0.000276	0.000536	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—kidney cancer	0.000274	0.000532	CcSEcCtD
L-DOPA—Discomfort—Capecitabine—kidney cancer	0.000274	0.000531	CcSEcCtD
L-DOPA—Pruritus—Gemcitabine—kidney cancer	0.000274	0.000531	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—kidney cancer	0.000272	0.000529	CcSEcCtD
L-DOPA—Dry mouth—Capecitabine—kidney cancer	0.000271	0.000526	CcSEcCtD
L-DOPA—Nausea—Dactinomycin—kidney cancer	0.000271	0.000526	CcSEcCtD
L-DOPA—Dizziness—Vincristine—kidney cancer	0.00027	0.000523	CcSEcCtD
L-DOPA—Confusional state—Capecitabine—kidney cancer	0.000268	0.00052	CcSEcCtD
L-DOPA—Feeling abnormal—Paclitaxel—kidney cancer	0.000267	0.000518	CcSEcCtD
L-DOPA—Oedema—Capecitabine—kidney cancer	0.000266	0.000516	CcSEcCtD
L-DOPA—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000265	0.000514	CcSEcCtD
L-DOPA—Diarrhoea—Gemcitabine—kidney cancer	0.000265	0.000513	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000263	0.000511	CcSEcCtD
L-DOPA—Shock—Capecitabine—kidney cancer	0.000261	0.000507	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—kidney cancer	0.000261	0.000506	CcSEcCtD
L-DOPA—Thrombocytopenia—Capecitabine—kidney cancer	0.00026	0.000505	CcSEcCtD
L-DOPA—Vomiting—Vincristine—kidney cancer	0.000259	0.000503	CcSEcCtD
L-DOPA—Urticaria—Paclitaxel—kidney cancer	0.000257	0.000499	CcSEcCtD
L-DOPA—Rash—Vincristine—kidney cancer	0.000257	0.000499	CcSEcCtD
L-DOPA—Hyperhidrosis—Capecitabine—kidney cancer	0.000257	0.000498	CcSEcCtD
L-DOPA—Dermatitis—Vincristine—kidney cancer	0.000257	0.000498	CcSEcCtD
L-DOPA—Abdominal pain—Paclitaxel—kidney cancer	0.000256	0.000497	CcSEcCtD
L-DOPA—Headache—Vincristine—kidney cancer	0.000255	0.000496	CcSEcCtD
L-DOPA—Anorexia—Capecitabine—kidney cancer	0.000253	0.000491	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—kidney cancer	0.000251	0.000486	CcSEcCtD
L-DOPA—Hypotension—Capecitabine—kidney cancer	0.000248	0.000482	CcSEcCtD
L-DOPA—Liothyronine—ABCB1—kidney cancer	0.000246	0.0133	CrCbGaD
L-DOPA—Vomiting—Gemcitabine—kidney cancer	0.000246	0.000477	CcSEcCtD
L-DOPA—Rash—Gemcitabine—kidney cancer	0.000244	0.000473	CcSEcCtD
L-DOPA—Dermatitis—Gemcitabine—kidney cancer	0.000244	0.000473	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—kidney cancer	0.000242	0.00047	CcSEcCtD
L-DOPA—Headache—Gemcitabine—kidney cancer	0.000242	0.00047	CcSEcCtD
L-DOPA—Nausea—Vincristine—kidney cancer	0.000242	0.00047	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—kidney cancer	0.000242	0.000469	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—kidney cancer	0.000241	0.000468	CcSEcCtD
L-DOPA—Insomnia—Capecitabine—kidney cancer	0.00024	0.000466	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—kidney cancer	0.00024	0.000465	CcSEcCtD
L-DOPA—Paraesthesia—Capecitabine—kidney cancer	0.000239	0.000463	CcSEcCtD
L-DOPA—Hypersensitivity—Paclitaxel—kidney cancer	0.000238	0.000463	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—kidney cancer	0.000238	0.000462	CcSEcCtD
L-DOPA—Dyspnoea—Capecitabine—kidney cancer	0.000237	0.00046	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—kidney cancer	0.000236	0.000459	CcSEcCtD
L-DOPA—Dyspepsia—Capecitabine—kidney cancer	0.000234	0.000454	CcSEcCtD
L-DOPA—Asthenia—Paclitaxel—kidney cancer	0.000232	0.000451	CcSEcCtD
L-DOPA—Decreased appetite—Capecitabine—kidney cancer	0.000231	0.000448	CcSEcCtD
L-DOPA—Nausea—Gemcitabine—kidney cancer	0.00023	0.000446	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000229	0.000445	CcSEcCtD
L-DOPA—Fatigue—Capecitabine—kidney cancer	0.000229	0.000444	CcSEcCtD
L-DOPA—Pruritus—Paclitaxel—kidney cancer	0.000229	0.000444	CcSEcCtD
L-DOPA—Constipation—Capecitabine—kidney cancer	0.000227	0.000441	CcSEcCtD
L-DOPA—Pain—Capecitabine—kidney cancer	0.000227	0.000441	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—kidney cancer	0.000224	0.000434	CcSEcCtD
L-DOPA—Diarrhoea—Paclitaxel—kidney cancer	0.000221	0.00043	CcSEcCtD
L-DOPA—Feeling abnormal—Capecitabine—kidney cancer	0.000219	0.000425	CcSEcCtD
L-DOPA—Gastrointestinal pain—Capecitabine—kidney cancer	0.000217	0.000422	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—kidney cancer	0.000215	0.000418	CcSEcCtD
L-DOPA—Dizziness—Paclitaxel—kidney cancer	0.000214	0.000415	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—kidney cancer	0.000213	0.000413	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—kidney cancer	0.000211	0.00041	CcSEcCtD
L-DOPA—Urticaria—Capecitabine—kidney cancer	0.000211	0.00041	CcSEcCtD
L-DOPA—Abdominal pain—Capecitabine—kidney cancer	0.00021	0.000408	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—kidney cancer	0.000207	0.000401	CcSEcCtD
L-DOPA—Tension—Doxorubicin—kidney cancer	0.000206	0.0004	CcSEcCtD
L-DOPA—Vomiting—Paclitaxel—kidney cancer	0.000206	0.000399	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—kidney cancer	0.000205	0.000399	CcSEcCtD
L-DOPA—Rash—Paclitaxel—kidney cancer	0.000204	0.000396	CcSEcCtD
L-DOPA—Dermatitis—Paclitaxel—kidney cancer	0.000204	0.000396	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—kidney cancer	0.000204	0.000395	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—kidney cancer	0.000203	0.000394	CcSEcCtD
L-DOPA—Headache—Paclitaxel—kidney cancer	0.000203	0.000394	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—kidney cancer	0.000202	0.000391	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—kidney cancer	0.000198	0.000384	CcSEcCtD
L-DOPA—Hypersensitivity—Capecitabine—kidney cancer	0.000196	0.00038	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—kidney cancer	0.000195	0.000378	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—kidney cancer	0.000194	0.000376	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—kidney cancer	0.000193	0.000374	CcSEcCtD
L-DOPA—Nausea—Paclitaxel—kidney cancer	0.000192	0.000373	CcSEcCtD
L-DOPA—Asthenia—Capecitabine—kidney cancer	0.000191	0.00037	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—kidney cancer	0.000189	0.000367	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—kidney cancer	0.000188	0.000365	CcSEcCtD
L-DOPA—Pruritus—Capecitabine—kidney cancer	0.000188	0.000365	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—kidney cancer	0.000188	0.000364	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—kidney cancer	0.000185	0.00036	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—kidney cancer	0.000184	0.000358	CcSEcCtD
L-DOPA—Cough—Doxorubicin—kidney cancer	0.000183	0.000355	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—kidney cancer	0.000182	0.000353	CcSEcCtD
L-DOPA—Diarrhoea—Capecitabine—kidney cancer	0.000182	0.000353	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—kidney cancer	0.000181	0.000352	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—kidney cancer	0.000179	0.000347	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—kidney cancer	0.000178	0.000345	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—kidney cancer	0.000176	0.000343	CcSEcCtD
L-DOPA—Dizziness—Capecitabine—kidney cancer	0.000176	0.000341	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—kidney cancer	0.000175	0.000339	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—kidney cancer	0.000173	0.000335	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—kidney cancer	0.000171	0.000332	CcSEcCtD
L-DOPA—Vomiting—Capecitabine—kidney cancer	0.000169	0.000328	CcSEcCtD
L-DOPA—Shock—Doxorubicin—kidney cancer	0.000168	0.000327	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—kidney cancer	0.000168	0.000325	CcSEcCtD
L-DOPA—Rash—Capecitabine—kidney cancer	0.000167	0.000325	CcSEcCtD
L-DOPA—Dermatitis—Capecitabine—kidney cancer	0.000167	0.000325	CcSEcCtD
L-DOPA—Headache—Capecitabine—kidney cancer	0.000166	0.000323	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—kidney cancer	0.000166	0.000321	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—kidney cancer	0.000163	0.000317	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—kidney cancer	0.00016	0.000311	CcSEcCtD
L-DOPA—Nausea—Capecitabine—kidney cancer	0.000158	0.000306	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—kidney cancer	0.000155	0.000301	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—kidney cancer	0.000154	0.000298	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—kidney cancer	0.000153	0.000296	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—kidney cancer	0.000152	0.000295	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—kidney cancer	0.000151	0.000293	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—kidney cancer	0.000149	0.000289	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000148	0.000287	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—kidney cancer	0.000148	0.000287	CcSEcCtD
L-DOPA—Pain—Doxorubicin—kidney cancer	0.000146	0.000284	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—kidney cancer	0.000146	0.000284	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—kidney cancer	0.000141	0.000274	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—kidney cancer	0.00014	0.000272	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—kidney cancer	0.000136	0.000264	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—kidney cancer	0.000135	0.000263	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—kidney cancer	0.000126	0.000245	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—kidney cancer	0.000123	0.000238	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—kidney cancer	0.000121	0.000235	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—kidney cancer	0.000117	0.000227	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—kidney cancer	0.000113	0.00022	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—kidney cancer	0.000109	0.000211	CcSEcCtD
L-DOPA—Rash—Doxorubicin—kidney cancer	0.000108	0.00021	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—kidney cancer	0.000108	0.000209	CcSEcCtD
L-DOPA—Headache—Doxorubicin—kidney cancer	0.000107	0.000208	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—kidney cancer	0.000102	0.000197	CcSEcCtD
L-DOPA—DRD4—Signaling Pathways—TSC1—kidney cancer	4.4e-05	0.000254	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ANXA1—kidney cancer	4.4e-05	0.000254	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF2—kidney cancer	4.37e-05	0.000252	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN2B—kidney cancer	4.35e-05	0.000251	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—kidney cancer	4.29e-05	0.000248	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNA1—kidney cancer	4.28e-05	0.000247	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPC3—kidney cancer	4.27e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FLT1—kidney cancer	4.26e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HSPB1—kidney cancer	4.26e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EIF4EBP1—kidney cancer	4.26e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1R—kidney cancer	4.23e-05	0.000244	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNA1—kidney cancer	4.22e-05	0.000244	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HSPB1—kidney cancer	4.2e-05	0.000243	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EIF4EBP1—kidney cancer	4.2e-05	0.000243	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKAP13—kidney cancer	4.19e-05	0.000242	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP2—kidney cancer	4.19e-05	0.000242	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CA2—kidney cancer	4.15e-05	0.00024	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—RAF1—kidney cancer	4.07e-05	0.000235	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALAD—kidney cancer	4.05e-05	0.000234	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL2—kidney cancer	4.02e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—POMC—kidney cancer	4.01e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TSC1—kidney cancer	3.96e-05	0.000229	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PSMD7—kidney cancer	3.96e-05	0.000229	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ANXA1—kidney cancer	3.96e-05	0.000229	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ST3GAL2—kidney cancer	3.95e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUNB—kidney cancer	3.95e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PAK1—kidney cancer	3.95e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PSMD7—kidney cancer	3.9e-05	0.000225	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ANXA1—kidney cancer	3.9e-05	0.000225	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TSC1—kidney cancer	3.9e-05	0.000225	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALDH1A1—kidney cancer	3.86e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GRB7—kidney cancer	3.83e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FLT1—kidney cancer	3.83e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FLT1—kidney cancer	3.78e-05	0.000218	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC5A3—kidney cancer	3.7e-05	0.000214	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PGK1—kidney cancer	3.7e-05	0.000214	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2—kidney cancer	3.65e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—POMC—kidney cancer	3.65e-05	0.000211	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LDHB—kidney cancer	3.63e-05	0.00021	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—POMC—kidney cancer	3.61e-05	0.000209	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—POMC—kidney cancer	3.57e-05	0.000206	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ITPR2—kidney cancer	3.57e-05	0.000206	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUNB—kidney cancer	3.55e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PAK1—kidney cancer	3.55e-05	0.000205	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—kidney cancer	3.54e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUNB—kidney cancer	3.51e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PAK1—kidney cancer	3.51e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HIF1A—kidney cancer	3.48e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TSC2—kidney cancer	3.47e-05	0.0002	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KDR—kidney cancer	3.33e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—POMC—kidney cancer	3.28e-05	0.00019	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—POMC—kidney cancer	3.24e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNA1—kidney cancer	3.23e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF2—kidney cancer	3.23e-05	0.000186	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EIF4EBP1—kidney cancer	3.21e-05	0.000186	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HSPB1—kidney cancer	3.21e-05	0.000186	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN2B—kidney cancer	3.21e-05	0.000186	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CA9—kidney cancer	3.15e-05	0.000182	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1R—kidney cancer	3.12e-05	0.00018	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTEN—kidney cancer	3.09e-05	0.000178	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KIT—kidney cancer	3.07e-05	0.000177	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APC—kidney cancer	3.07e-05	0.000177	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—RAF1—kidney cancer	3.01e-05	0.000174	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PSMD7—kidney cancer	2.99e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSC1—kidney cancer	2.99e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ANXA1—kidney cancer	2.99e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2—kidney cancer	2.97e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK3—kidney cancer	2.94e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—POMC—kidney cancer	2.92e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF2—kidney cancer	2.9e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FLT1—kidney cancer	2.89e-05	0.000167	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN2B—kidney cancer	2.89e-05	0.000167	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—BRAF—kidney cancer	2.88e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF2—kidney cancer	2.87e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN2B—kidney cancer	2.85e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1R—kidney cancer	2.81e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK1—kidney cancer	2.79e-05	0.000161	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1R—kidney cancer	2.77e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—POMC—kidney cancer	2.73e-05	0.000158	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RAF1—kidney cancer	2.71e-05	0.000156	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—kidney cancer	2.7e-05	0.000156	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUNB—kidney cancer	2.68e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PAK1—kidney cancer	2.68e-05	0.000155	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CRABP1—kidney cancer	2.68e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—kidney cancer	2.67e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RAF1—kidney cancer	2.67e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CA—kidney cancer	2.67e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—kidney cancer	2.64e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—kidney cancer	2.64e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HIF1A—kidney cancer	2.57e-05	0.000148	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TSC2—kidney cancer	2.56e-05	0.000148	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ITPR2—kidney cancer	2.49e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—POMC—kidney cancer	2.48e-05	0.000143	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KDR—kidney cancer	2.46e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—kidney cancer	2.43e-05	0.00014	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—kidney cancer	2.42e-05	0.00014	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RAF1—kidney cancer	2.41e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RELA—kidney cancer	2.4e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—kidney cancer	2.39e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—kidney cancer	2.38e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MTOR—kidney cancer	2.35e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIF1A—kidney cancer	2.31e-05	0.000134	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TSC2—kidney cancer	2.31e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIF1A—kidney cancer	2.28e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TSC2—kidney cancer	2.28e-05	0.000131	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ACHE—kidney cancer	2.27e-05	0.000131	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTT1—kidney cancer	2.27e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APC—kidney cancer	2.26e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KIT—kidney cancer	2.26e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KDR—kidney cancer	2.21e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1B—kidney cancer	2.2e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF2—kidney cancer	2.19e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN2B—kidney cancer	2.18e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—kidney cancer	2.18e-05	0.000126	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—kidney cancer	2.18e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK3—kidney cancer	2.17e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—kidney cancer	2.16e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—POMC—kidney cancer	2.15e-05	0.000124	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SCARB1—kidney cancer	2.15e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—BRAF—kidney cancer	2.13e-05	0.000123	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS1—kidney cancer	2.13e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—kidney cancer	2.12e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—kidney cancer	2.1e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—kidney cancer	2.1e-05	0.000121	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PSMD7—kidney cancer	2.08e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNB1—kidney cancer	2.08e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK1—kidney cancer	2.06e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RAF1—kidney cancer	2.04e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIT—kidney cancer	2.04e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APC—kidney cancer	2.04e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—kidney cancer	2.03e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—kidney cancer	2.02e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—kidney cancer	2.01e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KIT—kidney cancer	2.01e-05	0.000116	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BCHE—kidney cancer	1.98e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—kidney cancer	1.97e-05	0.000114	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.95e-05	0.000113	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK3—kidney cancer	1.95e-05	0.000113	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—kidney cancer	1.95e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—POMC—kidney cancer	1.94e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK3—kidney cancer	1.92e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—kidney cancer	1.91e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—POMC—kidney cancer	1.91e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—kidney cancer	1.89e-05	0.000109	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.88e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK1—kidney cancer	1.86e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—kidney cancer	1.83e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—kidney cancer	1.83e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK1—kidney cancer	1.83e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—kidney cancer	1.79e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RAF1—kidney cancer	1.78e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—kidney cancer	1.77e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RELA—kidney cancer	1.77e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—kidney cancer	1.76e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—kidney cancer	1.75e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—kidney cancer	1.75e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—kidney cancer	1.75e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSC2—kidney cancer	1.74e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK3—kidney cancer	1.73e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MTOR—kidney cancer	1.73e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—kidney cancer	1.73e-05	9.99e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—kidney cancer	1.69e-05	9.74e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—kidney cancer	1.67e-05	9.64e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK1—kidney cancer	1.65e-05	9.53e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1B—kidney cancer	1.63e-05	9.4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—kidney cancer	1.61e-05	9.3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RAF1—kidney cancer	1.6e-05	9.23e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—kidney cancer	1.59e-05	9.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RELA—kidney cancer	1.59e-05	9.19e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—kidney cancer	1.59e-05	9.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—kidney cancer	1.58e-05	9.13e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RAF1—kidney cancer	1.58e-05	9.11e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—kidney cancer	1.57e-05	9.08e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RELA—kidney cancer	1.57e-05	9.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MTOR—kidney cancer	1.56e-05	9.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—kidney cancer	1.56e-05	9.01e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—kidney cancer	1.56e-05	9e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—kidney cancer	1.55e-05	8.96e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—kidney cancer	1.55e-05	8.94e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MTOR—kidney cancer	1.54e-05	8.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—kidney cancer	1.54e-05	8.88e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—kidney cancer	1.54e-05	8.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—kidney cancer	1.54e-05	8.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—kidney cancer	1.5e-05	8.65e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—kidney cancer	1.49e-05	8.59e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK3—kidney cancer	1.47e-05	8.5e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1B—kidney cancer	1.46e-05	8.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—POMC—kidney cancer	1.46e-05	8.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—kidney cancer	1.45e-05	8.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1B—kidney cancer	1.45e-05	8.35e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—kidney cancer	1.44e-05	8.34e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—kidney cancer	1.43e-05	8.28e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—kidney cancer	1.43e-05	8.27e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—kidney cancer	1.41e-05	8.17e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK1—kidney cancer	1.4e-05	8.09e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—kidney cancer	1.4e-05	8.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—kidney cancer	1.39e-05	8.05e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—kidney cancer	1.39e-05	8e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—kidney cancer	1.38e-05	7.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—kidney cancer	1.38e-05	7.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—kidney cancer	1.38e-05	7.94e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.37e-05	7.91e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—kidney cancer	1.37e-05	7.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—kidney cancer	1.35e-05	7.81e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—kidney cancer	1.35e-05	7.79e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	1.34e-05	7.73e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—kidney cancer	1.33e-05	7.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—kidney cancer	1.32e-05	7.64e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK3—kidney cancer	1.28e-05	7.39e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—kidney cancer	1.24e-05	7.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—kidney cancer	1.22e-05	7.03e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK1—kidney cancer	1.22e-05	7.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	1.22e-05	7.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RAF1—kidney cancer	1.21e-05	6.97e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—kidney cancer	1.2e-05	6.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RELA—kidney cancer	1.2e-05	6.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—kidney cancer	1.19e-05	6.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MTOR—kidney cancer	1.18e-05	6.8e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK3—kidney cancer	1.15e-05	6.65e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—kidney cancer	1.15e-05	6.64e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK3—kidney cancer	1.14e-05	6.57e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—kidney cancer	1.12e-05	6.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1B—kidney cancer	1.11e-05	6.39e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—kidney cancer	1.11e-05	6.39e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK1—kidney cancer	1.1e-05	6.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—kidney cancer	1.08e-05	6.25e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK1—kidney cancer	1.08e-05	6.25e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—kidney cancer	1.06e-05	6.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—kidney cancer	1.05e-05	6.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—kidney cancer	1.05e-05	6.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—kidney cancer	1.04e-05	6.03e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—kidney cancer	1.04e-05	5.98e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—kidney cancer	1.02e-05	5.9e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—kidney cancer	1.02e-05	5.9e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—POMC—kidney cancer	1.02e-05	5.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—kidney cancer	1.02e-05	5.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—kidney cancer	9.51e-06	5.49e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—kidney cancer	9.39e-06	5.42e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—kidney cancer	9.2e-06	5.31e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—kidney cancer	9.2e-06	5.31e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—kidney cancer	9.08e-06	5.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK3—kidney cancer	8.7e-06	5.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—kidney cancer	8.46e-06	4.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK1—kidney cancer	8.28e-06	4.78e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—kidney cancer	8.14e-06	4.7e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—kidney cancer	7.82e-06	4.51e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—kidney cancer	7.18e-06	4.15e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—kidney cancer	7.1e-06	4.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—kidney cancer	6.95e-06	4.01e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—kidney cancer	5.01e-06	2.89e-05	CbGpPWpGaD
